AIA Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $224K | Sell |
1,781
-150
| -8% | -$18.9K | ﹤0.01% | 322 |
|
|
2025
Q1 | $214K | Buy |
1,931
+230
| +14% | +$25.4K | 0.01% | 312 |
|
|
2024
Q4 | $232K | Buy |
+1,701
| New | +$232K | 0.01% | 288 |
|
|
2023
Q2 | – | Sell |
-2,105
| Closed | -$213K | – | 448 |
|
|
2023
Q1 | $213K | Sell |
2,105
-319
| -13% | -$32.3K | 0.01% | 317 |
|
|
2022
Q4 | $290K | Buy |
+2,424
| New | +$290K | 0.02% | 285 |
|
|
2022
Q3 | – | Sell |
-1,640
| Closed | -$160K | – | 436 |
|
|
2022
Q2 | $160K | Buy |
+1,640
| New | +$160K | 0.01% | 400 |
|